Reflecting on Errors and Missed Opportunities in HER2-Positive Breast Cancer

Hematology-Oncology
Curriculum:
Reflecting on Errors and Missed Opportunities in HER2-positive Breast Cancer
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
August 25, 2016
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists and oncology nurse practitioners (NPs) and physician assistants (PAs)

Relevant Terms:

Breast cancer, HER2-positive breast cancer

Ruth M. O'Regan, MD

Ruth M. O'Regan, MD
Chief, Division of Hematology/Oncology and Palliative Care
Endowed Professor of Hematology/Oncology
Department of Medicine
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

Ruth O’Regan, MD, is Division Chief of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin.  She previously was the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Emory University, in addition to medical director at Glenn Family Breast Center of Emory University, and director of the Breast Cancer Translational Research Program at the Winship Cancer Institute.
 
 
 

Hope S. Rugo, MD

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Hope S. Rugo, MD, is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education.
 
With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. In addition, she completed a 2-year postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care Physician of the Year Award in 2010.
 
Dr. Rugo's research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care. She is an investigator in the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is 1 of 3 recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials.
 
Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of breast cancer and supportive care-related topics
1. Utilize the updated ASCO/CAP 2013 guidelines to improve detection and classification of HER2 status
2. Apply current efficacy and safety data to select targeted treatments that improve outcomes for patients with HER2-positive BCa
3. Apply current guideline-recommended neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive BCa
4. Effectively engage patients with HER2-positive BCa in their healthcare by implementing effective shared decision-making strategies

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC
 
PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Ruth M. O’Regan, MD, has no affiliations with commercial interests to disclose.
  • Hope S. Rugo, MD, has affiliations with Genomic health (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); GSK, Genentech/Roche, Novartis, Lilly, Pfizer, Eisai, Merck, OBI, Macrogenics, Plexxikon (Research).
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Scott Korber, MBA, has no affiliations with commercial interests to disclose.
  • Nora Hartley has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
  
Estimated time to complete: 1.0 hours
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Genentech.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above